TY  - GEN
AU  - Patel,Mallika P
AU  - Woodring,Sarah
AU  - Randazzo,Dina M
AU  - Friedman,Henry S
AU  - Desjardins,Annick
AU  - Healy,Patrick
AU  - Herndon,James E
AU  - McSherry,Frances
AU  - Lipp,Eric S
AU  - Miller,Elizabeth
AU  - Peters,Katherine B
AU  - Affronti,Mary Lou
TI  - Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide
SN  - 1433-7339
PY  - 2020///0625
KW  - Adult
KW  - Aged
KW  - Antiemetics
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Aprepitant
KW  - Brain Neoplasms
KW  - drug therapy
KW  - Female
KW  - Glioma
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Nausea
KW  - chemically induced
KW  - Ondansetron
KW  - Quality of Life
KW  - Temozolomide
KW  - Vomiting
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1007/s00520-019-05039-x
ER  -